EPAS1 and renal cell carcinoma: PT2385 selectively binds HIF-2α (Kd < 50 nM)—but not HIF-1α—to prevent it from binding to HIF-1β and has shown promise in preclinical studies (22) and clinical trials on patients with renal cell carcinoma (23, 24).